Systemic Treatments for Recurrent or Metastatic Sinonasal Carcinomas: A Retrospective Multicenter Study.

Area of Science:

• Oncology
• Head and Neck Cancer Research
• Rare Cancer Studies

Background:

• Sinonasal cancers are rare, heterogeneous, and present a significant therapeutic challenge in advanced stages.
• Limited data exists on effective systemic management for recurrent or metastatic sinonasal carcinomas.

Purpose of the Study:

• To analyze the outcomes of systemic therapy in patients with advanced sinonasal carcinomas.
• To identify treatment patterns and survival data for rare sinonasal cancer subtypes.

Main Methods:

• Retrospective multicenter study of 83 patients with recurrent/metastatic sinonasal carcinomas (excluding SCC and ACC) treated between 2012-2021.
• Data collected from REFCOR and Onco-Occitanie databases for standardized analysis.
• Focus on first-line platinum-based chemotherapy regimens.

Main Results:

• Intestinal-type adenocarcinomas, undifferentiated sinonasal carcinomas, and olfactory neuroblastomas were main subtypes.
• Median overall survival was 13.6 months; median progression-free survival was 5.3 months.
• Platinum-based chemotherapy showed a 73.6% disease control rate; targeted therapies and immunotherapy were rarely utilized.

Conclusions:

• Current systemic chemotherapy provides modest survival benefits for advanced sinonasal cancers.
• Genomic sequencing and clinical trial enrollment are crucial for developing improved therapeutic strategies.